Organization (Other)
Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov lists Barbara Ann Karmanos Cancer Institute as lead sponsor of 160 trials. It has 184 active development programs and 84 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 9 registered with a 2026 start date. The dashed outline is the pace from the 7 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Barbara Ann Karmanos Cancer Institute: 160 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (123)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 27 |
| Multiple Myeloma | 25 |
| Breast Neoplasms | 25 |
| Prostatic Neoplasms | 24 |
| Carcinoma, Non-Small-Cell Lung | 19 |
Showing 5 of 123 disease areas.
Trials by start year as sponsor or collaborator (34)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 9 |
| 2025 | 5 |
| 2024 | 2 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 4 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 9 |
| 2017 | 6 |
Showing 10 of 34 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 12 trials still running at the 2026-10-09 snapshot; registered median of 50 months across 130 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (184)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| CYCLOPHOSPHAMIDE | Lymphoma, Large B-Cell, Diffuse | Phase 2 | 4 |
| CYCLOPHOSPHAMIDE | Lymphoma | Phase 2 | 4 |
| CYCLOPHOSPHAMIDE | Lymphoma, Non-Hodgkin | Phase 2 | 4 |
| CYCLOPHOSPHAMIDE | Lymphoma, B-Cell | Phase 2 | 4 |
| RITUXIMAB | Lymphoma | Phase 2 | 3 |
Showing 5 of 184 active programs.
Approved assets (84)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| FILGRASTIM | 4 |
| GEMCITABINE | 11 |
| DOCETAXEL | 10 |
| CYCLOPHOSPHAMIDE | 9 |
| DEXAMETHASONE | 8 |
Showing 5 of 84 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 15% hit target (n=39) | 25% on time (n=36) |
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| KARMANOS CANCER INSTITUTE | Certificate of accreditation | Active |
| KARMANOS CANCER CENTER | Certificate of waiver | Active |
| BARBARA ANN KARMANOS CANCER INSTITUTE | Certificate for PPM procedures | Terminated |
Biomarker capability evidence (409)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ABO | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 409 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and organization relationships.
Counted at group level under McLaren Health Care: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.